7/23/2024

Janusmed kön och genus

Janusmed kön och genus – Doxorubicin

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Doxorubicin

Doxorubicin

Klass : C

  1. Radkiewicz, C. Sex differences in cancer risk and survival. [dissertation]. Dept of Medical Epidemiology and Biostatistics: Karolinska Institutet; 2019.
  2. Edgren G, Liang L, Adami HO, Chang ET. Enigmatic sex disparities in cancer incidence. Eur J Epidemiol. 2012;27(3):187-96.
  3. Doxorubicin Accord (doxorubicin). Summary of Product Characteristics. Swedish Medical Products Agency [updated 2019-03-29, cited 2021-06-22]
  4. Doxorubicin Hydrochloride. DailyMed [www]. US National Library of Medicine. [updated 2019-12-31, cited 2021-06-22].
  5. Baudry E, Huguet S, Couderc AL, Chaibi P, Bret F, Verny C et al. Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. Cancer Chemother Pharmacol. 2019;83(4):775-785.
  6. Rudek MA, Sparreboom A, Garrett-Mayer ES, Armstrong DK, Wolff AC, Verweij J, Baker SD. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer. 2004;40(8):1170-8.
  7. La-Beck NM, Zamboni BA, Gabizon A, Schmeeda H, Amantea M, Gehrig PA, Zamboni WC. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemother Pharmacol. 2012;69(1):43-50.
  8. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data Sarcoma Meta-analysis Collaboration. Lancet. 1997;350(9092):1647-54.
  9. Koziner B, Sklaroff R, Little C, Labriola D, Thaler HT, Straus DJ, Young CW, Nisce LZ, Oettgen H, Lee BJ 3rd, et al. NHL-3 protocol Six-drug combination chemotherapy for non-Hodgkin's lymphoma. Cancer. 1984;53(12):2592-600.
  10. Alvegard TA, Berg NO, Baldetorp B, Fernö M, Killander D, Ranstam J et al. Cellular DNA content and prognosis of high-grade soft tissue sarcoma: the Scandinavian Sarcoma Group experience. J Clin Oncol. 1990;8(3):538-47.
  11. Toma S, Canavese G, Grimaldi A, Ravera G, Ugolini D, Percivale P et al. Concomitant chemo-radiotherapy in the treatment of locally advanced and/or metastatic soft tissue sarcomas: experience of the National Cancer Institute of Genoa. Oncol Rep. 2003;10(3):641-7.
  12. Dana BW, Dahlberg S, Nathwani BN, Chase E, Coltman C, Miller TP et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol. 1993;11(4):644-51.
  13. Maksymiuk AW, Jett JR, Earle JD, Su JQ, Diegert FA, Mailliard JA et al. Sequencing and schedule effects of cisplatin plus etoposide in small-cell lung cancer: results of a North Central Cancer Treatment Group randomized clinical trial. J Clin Oncol. 1994;12(1):70-6.
  14. Sieber M, Tesch H, Pfistner B, Rueffer U, Paulus U, Munker R et al. Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Ann Oncol. 2004;15(2):276-82.
  15. Maurer LH, Pajak T, Eaton W, Comis R, Chahinian P, Faulkner C et al. Combined modality therapy with radiotherapy, chemotherapy, and immunotherapy in limited small-cell carcinoma of the lung: a Phase III cancer and Leukemia Group B Study. J Clin Oncol. 1985;3(7):969-76.
  16. Singh S, Parulekar W, Murray N, Feld R, Evans WK, Tu D et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer. J Clin Oncol. 2005;23(4):850-6.
  17. Young RJ, Litière S, Lia M, Hogendoorn PCW, Fisher C, Mechtersheimer G et al. Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. Acta Oncol. 2017;56(7):1013-1020.
  18. Kühnl A, Cunningham D, Counsell N, Hawkes EA, Qian W, Smith P, Chadwick N, Lawrie A, Mouncey P, Jack A, Pocock C, Ardeshna KM, Radford J, McMillan A, Davies J, Turner D, Kruger A, Johnson PW, Gambell J, Rosenwald A, Ott G, Horn H, Ziepert M, Pfreundschuh M, Linch D. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial. Ann Oncol. 2017;28(7):1540-1546.
  19. Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF Jr, Smith TL, Williams D, Logothetis CJ. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer. J Clin Oncol. 2002;20(5):1361-7.
  20. Brada M, Hjiyiannakis D, Hines F, Traish D, Ashley S. Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL). Int J Radiat Oncol Biol Phys. 1998;40(5):1157-62.
  21. Longo DL, Glatstein E, Duffey PL, Young RC, Ihde DC, Bastian AW et al. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. J Clin Oncol. 1997;15(11):3338-46.
  22. Köppler H, Pflüger KH, Eschenbach I, Pfab R, Birkmann J, Zeller W, Holle R, Steinhauer UE, Gropp C, Oehl S, et al. Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial. Ann Oncol. 1994;5(1):49-55.
  23. Igawa M, Ohkuchi T, Ueda M, Usui T. Factors affecting the outcome of patients with advanced urothelial cancer following chemotherapy with methotrexate, vinblastine, adriamycin, and cisplatin. Cancer Chemother Pharmacol. 1992;30 Suppl:S77-80.
  24. Schneider AM, Straus DJ, Schluger AE, Lowenthal DA, Koziner B, Lee BJ et al. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas. J Clin Oncol. 1990;8(1):94-102.
  25. Nakamura N, Hara T, Shibata Y, Matsumoto T, Nakamura H, Ninomiya S, Kito Y, Kitagawa J, Kanemura N, Goto N, Shiraki M, Miyazaki T, Takeuchi T, Shimizu M, Tsurumi H. Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma. Ann Hematol. 2015;94(12):2043-53.
  26. Rosenblatt E, Abdel-Wahab M, El-Gantiry M, Elattar I, Bourque JM, Afiane M et al. Brachytherapy boost in loco-regionally advanced nasopharyngeal carcinoma: a prospective randomized trial of the International Atomic Energy Agency. Radiat Oncol. 2014;9:67.
  27. Bacci G, Ferrari S, Delepine N, Bertoni F, Picci P, Mercuri M et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol. 1998;16(2):658-63.
  28. Perry MC, Eaton WL, Propert KJ, Ware JH, Zimmer B, Chahinian AP et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med. 1987;316(15):912-8.
  29. Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.
  30. Martindale: The Complete Drug Reference. Pharmaceutical Press.
  31. ZINECARD (dexrazoxane). Summary of Product Charateristics. Drugs@FDA [www]. Food and Drug Administration (FDA). [updated 2014-04-01, cited 2021-08-23].
  32. Sleijfer S, Rizzo E, Litière S, Mathijssen RHJ, Judson IR, Gelderblom H et al. Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database. Acta Oncol. 2018;57(8):1117-1126.
  33. Paioli A, Luksch R, Fagioli F, Tamburini A, Cesari M, Palmerini E et al. Chemotherapy-related toxicity in patients with non-metastatic Ewing sarcoma: influence of sex and age. J Chemother. 2014;26(1):49-56.
  34. Ferrari S, Palmerini E, Staals E, Abate ME, Longhi A, Cesari M et al. Sex- and age-related chemotherapy toxicity in patients with non-metastatic osteosarcoma. J Chemother. 2009;21(2):205-10.
  35. Pater J, Slamet L, Zee B, Osoba D, Warr D, Rusthoven J. Inconsistency of prognostic factors for post-chemotherapy nausea and vomiting. Support Care Cancer. 1994;2(3):161-6.
  36. Eiser C, Stride CB, Vora A, Goulden N, Mitchell C, Buck G et al. Prospective evaluation of quality of life in children treated in UKALL 2003 for acute lymphoblastic leukaemia: A cohort study. Pediatr Blood Cancer. 2017;64(11):161-6.
  37. Eiser C, Stride CB, Vora A, Goulden N, Mitchell C, Buck G et al. Prospective evaluation of quality of life in children treated in UKALL 2003 for acute lymphoblastic leukaemia: A cohort study. Pediatr Blood Cancer. 2017;64(11):161-6.
  38. Conise (INSIKT). Kalmar: eHälsomyndigheten. 2018 [cited 2021-11-18.]